GlassScriptPhysician profile
Seth S Charatz
NPI 1801833850
$266,146.43
in general payments reported to CMS, 2019-2025
10 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $35K · 2021: $51K · 2022: $43K · 2023: $23K · 2024: $8,105 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $1,465 · Travel and Lodging: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,921.69 |
| Food and Beverage | $1,464.66 |
| Travel and Lodging | $1,234.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $122,986.98 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $59,798.85 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $41,223.96 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $19,073.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,233.88 | 2019-2021 | |
| Lilly USA, LLC | $10,420.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Mannkind Corporation | $650.00 | 2020 | |
| Ibsa Pharma INC. | $500.00 | 2022 | |
| Horizon Therapeutics Plc | $240.86 | 2020-2022 | |
| Abbott Laboratories | $18.74 | 2025 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Charatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.